Ascelia Pharma AB (publ) (STO:ACE)
Sweden · Delayed Price · Currency is SEK | Market Cap | 71.84M -82.3% |
| Revenue (ttm) | n/a |
| Net Income | -60.13M |
| EPS | -0.48 |
| Shares Out | 133.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 111,597 |
| Open | 0.5420 |
| Previous Close | 0.5560 |
| Day's Range | 0.5300 - 0.5500 |
| 52-Week Range | 0.4550 - 3.5500 |
| Beta | 0.89 |
| Analysts | n/a |
| Price Target | 1.95 (+262.45%) |
| Earnings Date | Nov 5, 2026 |
About Ascelia Pharma AB
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in M... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
The average 12-month stock price target for ACE is kr 1.95, which is an increase of 262.45% from the latest price.
News
Ascelia Pharma AB Transcript: Investor update
FDA discussions clarified product-quality requirements and opened a potential route to approval through reanalysis of SPARKLE images with a new endpoint, subject to further work and FDA alignment. Priorities include endpoint evaluation, partnering and assessing the European pathway.
Ascelia Pharma AB Press release: Investor update
Ascelia Pharma AB issued a press release on October 12, 2026, disclosing material business information to investors.
Ascelia Pharma AB Slides: Investor update
Ascelia Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on October 12, 2026.
Ascelia's H1 Loss Narrows; FDA Meeting On Orviglance Planned For Sept '26
(RTTNews) - Ascelia Pharma AB (publ) (ACE.ST), a biotech company, announced on Thursday financial results for the first half year, and registered significantly reduced losses as the company faced chal...
Ascelia Pharma AB Earnings Call Transcript: Q2 2026
Orviglance faces regulatory hurdles after an FDA Complete Response Letter, with a key Type A meeting set for September 9 to clarify approval requirements. Financials show a SEK 12 million Q2 deficit and SEK 38 million in liquidity, with cost reductions extending runway into Q2 2025.
Ascelia Pharma AB Quarterly report: Q2 2026
Ascelia Pharma AB has published its Q2 2026 quarterly earnings report on August 21, 2026.
Ascelia Pharma AB Slides: Q2 2026
Ascelia Pharma AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 21, 2026.
Ascelia Pharma AB Earnings Call Transcript: Q2 2026
Orviglance's FDA review resulted in a Complete Response Letter, delaying approval and partnership timelines, but the company remains confident in its data and is preparing for a key FDA meeting in September. Cost-saving actions have extended the cash runway into Q2 2027.
Ascelia Pharma AB Quarterly report: Q2 2026
Ascelia Pharma AB has published its Q2 2026 quarterly earnings report on August 20, 2026.
Ascelia Pharma AB Slides: Q2 2026
Ascelia Pharma AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 20, 2026.
Ascelia Pharma AB Transcript: ABGSC Investor Days
Major milestones are approaching with an FDA decision on Orviglance expected in early July and active partnering discussions underway. Orviglance targets a significant unmet need in liver imaging for cancer patients with renal disease, supported by strong clinical data and orphan drug exclusivity.
Ascelia Pharma AB Earnings Call Transcript: Q1 2026
Q1 saw steady operating losses and a strengthened cash position after a SEK 20 million raise. Orviglance is on track for FDA approval in July, with strong clinical data and active partnership discussions. Market trends favor non-gadolinium agents, supporting a positive outlook.
Ascelia Pharma AB Quarterly report: Q1 2026
Ascelia Pharma AB has published its Q1 2026 quarterly earnings report on May 13, 2026.
Ascelia Pharma AB Slides: Q1 2026
Ascelia Pharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Ascelia Pharma AB Earnings Call Transcript: Q1 2026
Q1 2026 saw progress toward FDA approval and commercialization of Orviglance, with strong clinical data and an extended cash runway into 2027 after a SEK 20 million share issue. Oncoral remains in the pipeline with phase II plans in gastric cancer.
Ascelia Pharma AB Quarterly report: Q1 2026
Ascelia Pharma AB has published its Q1 2026 quarterly earnings report on May 12, 2026.
Ascelia Pharma AB Slides: Q1 2026
Ascelia Pharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Ascelia Pharma AB Transcript: DNB Carnegie Healthcare Seminar 2026
Orviglance, a manganese-based liver MRI agent for patients with severe renal disease, is under FDA review with a July 3 PDUFA date and strong Phase 3 data. Commercialization will rely on partnerships, and the company is also advancing Oncoral, an oral irinotecan, into further development.
Ascelia Pharma AB Earnings Call Transcript: Q4 2025
Lead program Orviglance is in FDA review with a decision expected by July, targeting a significant unmet need in liver imaging for cancer patients with severe renal impairment. Financials show a SEK 16 million Q4 loss and SEK 50 million cash, with partnership discussions and launch preparations progressing well.
Ascelia Pharma AB Annual report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 annual report on February 6, 2026.
Ascelia Pharma AB Quarterly report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 quarterly earnings report on February 6, 2026.
Ascelia Pharma AB Slides: Q4 2025
Ascelia Pharma AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 6, 2026.
Ascelia Pharma AB Earnings Call Transcript: Q4 2025
Orviglance is on track for FDA approval in July 2026, targeting an $800M global market for liver MRI contrast in cancer patients with severe kidney impairment. Q4 saw a SEK 16M operating loss, SEK 15M in liquid assets, and ongoing partnering discussions for commercialization.
Ascelia Pharma AB Annual report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 annual report on February 5, 2026.
Ascelia Pharma AB Quarterly report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 quarterly earnings report on February 5, 2026.